Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade

Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade

Abstract Backgrounds Immune checkpoint blockade (ICB) is widely considered to exert long-term treatment benefits by activating antitumor immunity. However, many cancer patients show poor clinical responses to ICB due in part to the lack of an immunogenic niche. Focal adhesion kinase (FAK) is frequen...

Full description

Bibliographic Details
Main Authors: Baoyuan Zhang, Ning Li, Jiaming Gao, Yuxi Zhao, Jun Jiang, Shuang Xie, Cuiping Zhang, Qingyu Zhang, Leo Liu, Zaiqi Wang, Dongmei Ji, Lingying Wu, Ruibao Ren
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
FAK
Pegylated liposome doxorubicin (PLD)
Synergy
Immunogenic cell death (ICD)
Immune checkpoint blockade (ICB)
Online Access:https://doi.org/10.1186/s13046-024-02974-4

Internet

https://doi.org/10.1186/s13046-024-02974-4

Similar Items